FDA Clears Way for Clinical Trial of HDP-101

FDA Clears Way for Clinical Trial of HDP-101

285975

FDA Clears Way for Clinical Trial of HDP-101

Heidelberg Pharma has been cleared in the U.S. to begin a clinical trial testing its investigational therapy HDP-101 for the treatment of multiple myeloma. The U.S. Food and Drug Administration (FDA) allowed the start of a Phase 1/2a trial following the submission of an investigational new drug (IND) application. The company expects to enroll the first patient and administer the first dose of HDP-101 by June. “We have been working towards this goal for many…

You must be logged in to read/download the full post.